Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)

Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders Growth (1y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -88.68%
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -58.11%
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 104.24%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -129.68%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -290.15%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -230.18%
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 59.59%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Sol-Gel Technologies 207.80 Mn 197.67 Mn - -57.49%

Historic Data

Download Data
DateValue
Mar 31, 2026 -57.49%
Dec 31, 2025 44.07%
Sep 30, 2025 -659.42%
Jun 30, 2025 591.50%
Mar 31, 2025 35.12%
Dec 31, 2024 -12.80%
Sep 30, 2024 86.87%
Jun 30, 2024 124.88%
Mar 31, 2024 -39.33%
Dec 31, 2023 12.86%
Sep 30, 2023 -73.99%
Jun 30, 2023 -1,509.72%
Mar 31, 2023 85.93%
Dec 31, 2022 -144.45%
Sep 30, 2022 -384.98%
Jun 30, 2022 -94.24%
Mar 31, 2022 40.86%
Dec 31, 2021 308.80%
Sep 30, 2021 114.51%
Jun 30, 2021 6.50%